Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8:16:1565150.
doi: 10.3389/fpsyt.2025.1565150. eCollection 2025.

Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis

Affiliations

Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis

Rocío Gómez-Ballesteros et al. Front Psychiatry. .

Abstract

Background: Multiple sclerosis is one of the most common causes of neurological disability in young adults, with major consequences for their future lives. Patients with early-stage relapsing-remitting multiple sclerosis (RRMS) experience uncertainty and intense emotions as the diagnosis is disclosed. Illness perception at this point can influence levels of adjustment, coping strategies, treatment adherence, and well-being of the patient. However, there is limited information on patient illness perception surrounding the diagnosis.

Objective: The aim of this study was to assess illness perception and associated factors in early-stage RRMS patients.

Methods: A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS, a disease duration of ≤ 3 years, and an Expanded Disability Status Scale (EDSS) score of 0-5.5 were included. The Brief-Illness Perception Questionnaire (B-IPQ) was used to assess the patients' cognitive and emotional representations of their illness. Different patient-reported measures were used to gather information on pain, fatigue, mood/anxiety, quality of life, symptom severity, feelings of hopelessness, perception of stigma, cognition, hand dexterity, gait, and workplace difficulties. A multivariate logistic regression analysis was performed to assess the association between the patients' illness perception and demographic and clinical characteristics, as well as patient-reported outcomes.

Results: A total of 189 patients were included (mean age: 36.1 ± 9.4 years, 71.4% females, mean disease duration: 1.4 ± 0.8 years). The median EDSS score was 1.0 (interquartile range: 0.0-2.0). A total of 36.5% of the patients (n=69/189) had a moderate-to-high threatening illness perception, and 45.5% thought that their disease was caused by psychological factors. Higher EDSS scores, symptom severity, poorer psychological quality of life, perception of stigma, and greater hopelessness were predictors of moderate-to-high threatening illness perception.

Conclusions: Threatening illness perceptions are common among patients with early-stage RRMS. Identifying these beliefs and their associated factors, and establishing individualized interventions, may help patients deal with their condition.

Keywords: early-stage; illness perception; individualized interventions; patient-reported outcome measures; psychological factors; relapsing-remitting multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

SS received payment for lecturing or travel expenses from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, and Novartis. RG-B and JM are employees of Roche Pharma Spain. JM-M has served on scientific advisory boards and/or has received speaking honoraria, research funding and support to attend scientific meetings from Biogen, Merck, Novartis, Roche and Teva. JS has received speaking honoraria, compensation for consulting services and support to attend scientific meetings from Almirall, Bayer, Biogen, Merck, Novartis, Sanofi, Roche and Teva. AA has received compensation for consulting services from Biogen, BMS, Sanofi, Roche, Janssen and Novartis, and speaking honoraria from Biogen, BMS, Sanofi, Roche, Janssen, Merck, Almirall, and Novartis. AC has received courses and honoraria for her participation as speaker/meeting moderator/symposia organizer from Alter, Almirall, Bayer, Bial, Biogen, Bristol-Myers-Squibb, Lilly, Merck-Serono, Mylan, Novartis, Roche, Sanofi-Genzyme, Teva, and UCB, and support to attend scientific meetings from Biogen, Bial, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. JS-M has received support to attend scientific meetings from Novartis, Merck, and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer, and Teva, and has participated in clinical trials from Biogen, Merck, and Roche. FB-H has received compensation for consulting services and speaking honoraria from Almirall, Biogen, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, and Teva. CC has received compensation for consulting services, speaking honoraria and support to attend scientific meetings and courses from Merck, Teva, Sanofi-Genzyme, Novartis, Biogen, Roche, and Bristol-Myers-Squibb. LBr has received compensation for consulting services, speaking honoraria and support to attend scientific meetings from Bayer, Celgene, Biogen, Genzyme, Merck, Novartis, Roche, Almirall and Teva. JDG-S has received compensation for consulting services and speaking honoraria from Biogen, Novartis, Merck, UCB, Sanofi-Genzyme, Roche, Almirall, and Teva. LN-C has received compensations from Sanofi-Genzyme, Merck, Biogen, and Roche. EA has received speaking honoraria from Roche, Novartis, Merck, Sanofi, and Biogen. MG-R has received speaking honoraria from Biogen, Sanofi, Almirall and Novartis. OC has participated in studies and has received speaking honoraria from Roche, Merck, Biogen, and Novartis. LG-T has received speaking honoraria from Biogen, Novartis, Merck, Bayer, Sanofi-Genzyme, Almirall, Roche and Teva. MH has participated in observational studies and has received compensation for consulting services and speaking honoraria from Roche, Merck, Sanofi, Biogen, Novartis and Bayer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Causes of multiple sclerosis reported by patients. aPsychological includes emotional causes, depression, anxiety, nervousness, stress; bUnknown includes chance or bad luck; cLifestyle includes smoking, diet, lack of physical exercise; dothers includes severe sunstroke, car accident, attention, limp, pregnancy, fatigue, tingling, intestinal causes, migraine, neurological alterations, sleep problems, female sex, traumatism and vision. B-IPQ, Brief-Illness Perception Questionnaire.
Figure 2
Figure 2
Patient perception of illness. Patients' illness perception in the different items of the Brief-Illness Perception Questionnaire.

Similar articles

References

    1. Zanghi A, Galgani S, Bellantonio P, Zaffaroni M, Borriello G, Inglese M, et al. Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotype. Eur J Neurol. (2023) 30:2736–44. doi: 10.1111/ene.15910, PMID: - DOI - PubMed
    1. Khan G, Hashim MJ. Epidemiology of multiple sclerosis: global, regional, national and sub-national-level estimates and future projections. J Epidemiol Glob Health. (2025) 15:21. doi: 10.1007/s44197-025-00353-6, PMID: - DOI - PMC - PubMed
    1. Fuchs TA, Schoonheim MM, Zivadinov R, Dwyer MG, Colato E, Weinstock Z, et al. Cognitive progression independent of relapse in multiple sclerosis. Mult Scler. (2024) 30:1468–78. doi: 10.1177/13524585241256540, PMID: - DOI - PubMed
    1. Ghajarzadeh M, Waubant E, Nourbakhsh B. Design recommendations for studies that evaluate multiple sclerosis fatigue interventions. Front Psychiatry. (2023) 14:1287344. doi: 10.3389/fpsyt.2023.1287344, PMID: - DOI - PMC - PubMed
    1. Lakin L, Davis BE, Binns CC, Currie KM, Rensel MR. Comprehensive approach to management of multiple sclerosis: addressing invisible symptoms-A narrative review. Neurol Ther. (2021) 10:75–98. doi: 10.1007/s40120-021-00239-2, PMID: - DOI - PMC - PubMed

LinkOut - more resources